SCHEMBL6673845

SCHEMBL6673845

CN(C)c1ccc(NS(=O)(=O)c2ccc(Br)c(C(=O)O)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
PKM P14618 1/20 0.58
CASP6 P55212 1/20 0.56
TDP1 Q9NUW8 3/20 0.55
ALDH1A1 P00352 3/20 0.55
LMNA P02545 3/20 0.55
MAPT P10636 2/20 0.55
MAPK1 P28482 1/20 0.55
GFER P55789 1/20 0.55
MCL1 Q07820 1/20 0.55
POLB P06746 1/20 0.51
PPARG P37231 1/20 0.45
RAB9A P51151 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
NR2E3 Q9Y5X4 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
HTT P42858 1/20 0.45
TSHR P16473 1/20 0.45
GPR27 Q9NS67 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674454 0.85 TDP1 (0.60) MEN1KMT2ATDP1ALDH1A1LMNA
SCHEMBL6675086 0.82 POLB (0.75) MEN1KMT2APKMCASP6ALDH1A1
SCHEMBL7542193 0.81 POLB (0.48) MEN1KMT2APKMTDP1ALDH1A1
SCHEMBL7535496 0.80 TDP1 (0.51) MEN1KMT2APKMTDP1ALDH1A1
SCHEMBL9997222 0.79 MCL1 (0.62) MEN1KMT2APKMCASP6ALDH1A1
SCHEMBL12597585 0.78 MEN1 (0.60) MEN1KMT2APKMCASP6ALDH1A1
SCHEMBL6674411 0.78 LMNA (0.67) MEN1KMT2APKMCASP6ALDH1A1
SCHEMBL6674707 0.77 ALDH1A1 (0.55) MEN1KMT2APKMTDP1ALDH1A1
SCHEMBL6681272 0.77 MAPT (0.55) TDP1ALDH1A1LMNAMAPTMAPK1
SCHEMBL19329450 0.77 ALDH1A1 (0.55) MEN1KMT2ATDP1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed
EP-1005453-B1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS TULARIK INC (US) 2004-10-27 EP disclosed
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US disclosed
US-6284923-B1 BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS TULARIK INC 2001-09-04 US disclosed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP disclosed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 MEN1 2231/4885KMT2A 3154/4885PKM 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.